methotrexate

Overview

Antifolate chemotherapy; high-dose methotrexate is the backbone of first-line therapy for primary CNS lymphoma.

Evidence in the corpus

  • All 46 r/r CNS lymphoma patients enrolled in the MSK ibrutinib phase I/II trial had previously received methotrexate, establishing it as the standard frontline therapy prior to BTK inhibition PMID:38995739.
  • In three treatment-naïve osteosarcoma (OS) biopsies, organoid response to MAP (methotrexate + doxorubicin + cisplatin) tracked post-resection necrosis: SARC0041 and SARC0064 (50% and 57% residual MAP viability) had 99% and 95% necrosis with no recurrence at 1,400/1,500 days; SARC0135 (73% residual MAP viability, 60% necrosis) relapsed within 200 days PMID:39305899.
  • Methotrexate was recorded as a prior immunosuppressive/anti-psoriatic exposure in some patients in the NB-UVB phototherapy mutation-burden cohort; it was not an intervention tested in this study. PMID:26950094

Resistance mechanisms

  • Not directly characterized in the corpus.

Cancer types (linked)

  • PCNSL
  • DLBCLNOS
  • OS — osteosarcoma (MAP regimen backbone; PDTO viability predicts surgical necrosis)

Sources

This page was processed by entity-page-writer on 2026-05-15.